Your browser doesn't support javascript.
loading
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.
Oster, Paul; Vaillant, Laurie; Riva, Erika; McMillan, Brynn; Begka, Christina; Truntzer, Caroline; Richard, Corentin; Leblond, Marine M; Messaoudene, Meriem; Machremi, Elisavet; Limagne, Emeric; Ghiringhelli, Francois; Routy, Bertrand; Verdeil, Gregory; Velin, Dominique.
Afiliação
  • Oster P; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Vaillant L; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Riva E; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • McMillan B; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Begka C; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Truntzer C; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Richard C; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Leblond MM; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Messaoudene M; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Machremi E; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Limagne E; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Ghiringhelli F; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Routy B; Research Centre for the University of Montréal (CRCHUM), Hematology-Oncology Division, Department of Medicine, University of Montreal Healthcare Centre (CHUM), Montreal, Quebec, Canada.
  • Verdeil G; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
  • Velin D; Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland dominique.velin@chuv.ch.
Gut ; 71(3): 457-466, 2022 03.
Article em En | MEDLINE | ID: mdl-34253574
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Infecções por Helicobacter / Neoplasias do Colo / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Gut Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Infecções por Helicobacter / Neoplasias do Colo / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: Gut Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça